OOIR: Observatory of International Research

Papers

(The median citation count of Diabetes Care is 5. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-09-01 to 2025-09-01.)

Article	Citations
In This Issue of Diabetes Care	1828
About the Artist: Laura Jacobsen, MD	1650
Issues and Events	1085
Response to Comment on Huh et al. Remnant Cholesterol Is an Independent Predictor of Type 2 Diabetes: A Nationwide Population-Based Cohort Study. Diabetes Care 2023;46:305–312	895
Interoceptive Awareness Is Associated With Impaired Awareness of Hypoglycemia in Adults With Type 1 Diabetes	654
Comment on Gyldenkerne et al. Negative Trend in Peripheral Artery Disease in Incident Type 2 Diabetes in Germany	626
Comment on Maddaloni et al. Bone-Vascular Axis Biomarkers: Enhancing Cardiovascular Risk Management in Type 2 Diabetes	591
Response to Comment on Meek et al. Reappearance of C-Peptide During the Third Trimester in Type 1 Diabetes Pregnancy: Pancreatic Regeneration or Fetal Hyperinsulinism? Diabetes Care 2021;44:1826–1834	537
Neuropathic Pain With and Without Diabetic Peripheral Neuropathy in Type 1 Diabetes	484
About the Artist: Abby Gregg	469
Response to Comments on Maddaloni et al. Osteoprotegerin, Osteopontin, and Osteocalcin Are Associated With Cardiovascular Events in Type 2 Diabetes: Insights From EXSCEL. Diabetes Care 2025;48:235–242	437
Comparative Effectiveness of Aspirin Dosing in Cardiovascular Disease and Diabetes Mellitus: A Subgroup Analysis of the ADAPTABLE Trial	388
Trends in Metformin Use Among Patients With Prediabetes: 2008–2020	382
Associations of Dietary Cholesterol Consumption With Incident Diabetes and Cardiovascular Disease: The Role of Genetic Variability in Cholesterol Absorption and Disease Predisposition	341
About the Artists: John B. Buse, MD, PhD, and Mary Beth Cassely, MSPH	336
Comparison of Insulin Titration Strategies for Glycemic Control in Type 2 Diabetes: A Systematic Review and Network Meta-analysis	322
Personalizing Physical Activity for Glucose Control Among Individuals With Type 2 Diabetes: Are We There Yet?	301
Severe Mental Illness and Type 2 Diabetes Outcomes and Complications: A Nationwide Cohort Study	278
The Effectiveness of Shared Decision-making for Diabetes Prevention: 24- and 36-Month Results From the Prediabetes Informed Decision and Education (PRIDE) Trial	273
Refining the Definition of Stage 1 Type 1 Diabetes: An Ontology-Driven Analysis of the Heterogeneity of Multiple Islet Autoimmunity	258
Persistence of Risk for Type 2 Diabetes After Gestational Diabetes Mellitus	239
Real-time Continuous Glucose Monitoring in the Intensive Care Unit: The Fifth Vital Sign	230
Demographic, Clinical, Management, and Outcome Characteristics of 8,004 Young Children With Type 1 Diabetes	229
Associations Between Glucose Metabolism Measures and Amyloid-β and Tau Load on PET 14 Years Later: Findings From the Framingham Heart Study	223
Diet-Related Lipidomic Signatures and Changed Type 2 Diabetes Risk in a Randomized Controlled Feeding Study With Mediterranean Diet and Traditional Chinese or Transitional Diets	215

Minimal Model–Derived Insulin Sensitivity Index Underestimates Insulin Sensitivity in Black Americans	207
Traveling Across Time Zones With Type 1 Diabetes: A Pilot Study Comparing Insulin Degludec With Insulin Glargine U100	204
Physical Activity for Type 2 Diabetes Prevention: Some Is Better Than None, More Is Better, and Earliest Is Best	203
Disparities in Sodium–Glucose Cotransporter 2 (SGLT2) Inhibitor Prescription and Dispensing in the Israeli Population—A Retrospective Cohort Study	193
Beliefs Around Hypoglycemia and Their Impacts on Hypoglycemia Outcomes in Individuals with Type 1 Diabetes and High Risks for Hypoglycemia Despite Using Advanced Diabetes Technologies	193
Glucagon Prescribing and Costs Among U.S. Adults With Diabetes, 2011–2021	193
The Use of Rescue Insulin in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE)	193
Socioeconomic Factors Play a More Important Role than Clinical Needs in the Use of SGLT2 Inhibitors and GLP-1 Receptor Agonists in People With Type 2 Diabetes	189
An Integrated Digital Health Care Platform for Diabetes Management With AI-Based Dietary Management: 48-Week Results From a Randomized Controlled Trial	188
Prevalence of Chronic Kidney Disease in Type 1 Diabetes Among Adults in the U.S.	180
The Portfolio Diet and Incident Type 2 Diabetes: Findings From the Women’s Health Initiative Prospective Cohort Study	176
Arterial Stiffness, Genetic Risk, and Type 2 Diabetes: A Prospective Cohort Study	174
Proinsulin–to–C-Peptide Ratio as a Marker of β-Cell Function in African American and European American Adults	166
Predictors of Diabetes Outcomes at 1 Year After Islet Autotransplantation: Data From a Multicenter Cohort Study	165
15. Management of Diabetes in Pregnancy: Standards of Care in Diabetes—2024	162
Disclosures: Standards of Care in Diabetes—2025	159
12. Retinopathy, Neuropathy, and Foot Care: Standards of Medical Care in Diabetes—2022	158
Plasma Tryptophan-Kynurenine Pathway Metabolites and Risk for Progression to End-Stage Kidney Disease in Patients With Type 2 Diabetes	152
Issues and Events	149
Issues and Events	148
Issues and Events	148
Effect of a Mobile Health Technology–Based Diabetes Education Program on Glucose Control in Patients With Type 2 Diabetes Initiating Premixed Insulin: A Prospective, Multicenter, Observational Study	146
Response to Comment on Seidu et al. Efficacy and Safety of Continuous Glucose Monitoring and Intermittently Scanned Continuous Glucose Monitoring in Patients With Type 2 Diabetes: A Systematic Review	146
About the Artist: Giorgio Baldini	145
COVID-19 Vaccination Prior to SARS-CoV-2 Infection Reduced Risk of Subsequent Diabetes Mellitus: A Real-World Investigation Using U.S. Electronic Health Records	143
Management and Outcomes of Severe Hypoglycemia Treated by Emergency Medical Services in the U.S. Upper Midwest	139
Physical Activity Is Associated With Improved Glycemic Outcomes in Newly Diagnosed Youth With Type 1 Diabetes: 4T Exercise Program	136
Euglycemic Ketoacidosis in Two Patients Without Diabetes After Introduction of Sodium–Glucose Cotransporter 2 Inhibitor for Heart Failure With Reduced Ejection Fraction	135
Health-Related Quality of Life and Health Utility After Metabolic/Bariatric Surgery Versus Medical/Lifestyle Intervention in Individuals With Type 2 Diabetes and Obesity: The ARMMS-T2D Study	134
Dietary Insulinemic Potential and Risk of Total and Cause-Specific Mortality in the Nurses’ Health Study and the Health Professionals Follow-up Study	133
Dulaglutide and Glomerular Hyperfiltration, Proteinuria, and Albuminuria in Youth With Type 2 Diabetes: Post Hoc Analysis of the AWARD-PEDS Study	131
Heterogeneity of Type 1 Diabetes at Diagnosis Supports Existence of Age-Related Endotypes	126
Plasma Metabolome, Long-term Body Weight Change, and Type 2 Diabetes in U.S. Individuals	126
Estimating Glycemia From HbA1c and CGM: Analysis of Accuracy and Sources of Discrepancy	126
Genetic Discovery and Risk Prediction for Type 1 Diabetes in Individuals Without High-Risk HLA-DR3/DR4 Haplotypes	126
Community-Based Peer Support for Diabetes Management: 24-Month Changes Relative to Comparison Communities	125
Comment on Bezin et al. GLP-1 Receptor Agonists and the Risk of Thyroid Cancer. Diabetes Care 2023;46:384–390	117
Association of Metabolic Syndrome With Neuroimaging and Cognitive Outcomes in the UK Biobank	115
Diabetic Truncal Neuropathy—Clinical and Radiological Image	111
Is Son Preference a Potential Risk Factor for Diabetes?	111
Disruption to Pattern but No Overall Increase in the Expected Incidence of Pediatric Diabetes During the First Three Years of the COVID-19 Pandemic in Ontario, Canada (March 2020–March 2023)	110
Glycemic Control, Cognitive Aging, and Impairment Among Diverse Hispanic/Latino Individuals: Study of Latinos– Investigation of Neurocognitive Aging (Hispanic Community Health Study/Study of Latinos)	110
Comment on Hamblin et al. Capillary Ketone Concentrations at the Time of Colonoscopy: A Cross-Sectional Study With Implications for SGLT2 Inhibitor–Treated Type 2 Diabetes. Diabetes Care 2021;44:e124–	107
Phenotype and Lifestyle Intervention: Potential for Predicting and Improving Metabolic Outcomes?	107
Response to Comment on Fahrmann et al. Modification of the Association Between Severe Hypoglycemia and Ischemic Heart Disease by Surrogates of Vascular Damage Severity in Type 1 Diabetes During ∼30 Ye	106
Trends in Racial and Ethnic Disparities in Early Glycemic Control Among Veterans Receiving Care in the Veterans Health Administration, 2008–2019	102
Differential Treatment Effects on β-Cell Function Using Model-Based Parameters in Type 2 Diabetes: Results From the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE)	101
The Glycemic Impact of Protein Ingestion in People With Type 1 Diabetes	101
The Broader Economic Value of Treatment for Diabetic Macular Edema	99
Health Care Utilization Trends Across the Transition Period in a National Cohort of Adolescents and Young Adults With Type 1 Diabetes	98

Influence of Gestational Diabetes Mellitus on Diabetes Risk and Glycemic Control in a Retrospective Population-Based Cohort	96
Islet Transplantation Versus Standard of Care for Type 1 Diabetes Complicated by Severe Hypoglycemia From the Collaborative Islet Transplant Registry and the T1D Exchange Registry	94
Inadequately Controlled Type 2 Diabetes and Hypercortisolism: Improved Glycemia With Mifepristone Treatment	93
Progression of Cerebral Small Vessel Disease Among Neurologically Asymptomatic Middle-Aged Individuals With Type 1 Diabetes	93
Artificial Sweeteners and Risk of Type 2 Diabetes in the Prospective NutriNet-Santé Cohort	91
Large-Scale Proteomics Improve Risk Prediction for Type 2 Diabetes	91
Large Language Model GPT-4 Compared to Endocrinologist Responses on Initial Choice of Glucose-Lowering Medication Under Conditions of Clinical Uncertainty	91
Clinical Prediction Models Combining Routine Clinical Measures Have High Accuracy in Identifying Youth-Onset Type 2 Diabetes Defined by Maintained Endogenous Insulin Secretion: The SEARCH for Diabetes	90
Health and Economic Impact and Cost-Effectiveness of Produce Prescriptions for Diabetes in 50 U.S. States: A Microsimulation Study	88
Association and Interaction of Genetics and Area-Level Socioeconomic Factors on the Prevalence of Type 2 Diabetes and Obesity	88
Prevalence, Progression, and Modifiable Risk Factors for Diabetic Retinopathy in Youth and Young Adults With Youth-Onset Type 1 and Type 2 Diabetes: The SEARCH for Diabetes in Youth Study	88
COVID-19–Related Multisystem Inflammatory Syndrome in Children Presenting With New-Onset Type 1 Diabetes in Severe Ketoacidosis: A Case Series	87
Association Between Diabetes and Gray Matter Atrophy Patterns in a General Older Japanese Population: The Hisayama Study	85
Effectiveness of Low Intensity Mental Health Support via a Telehealth Enabled Network (LISTEN) for Adults With Diabetes Distress: A Parallel Group, Pragmatic Randomized Controlled Trial	85
Rational Pharmacotherapy in Type 2 Diabetes: Danish Data From 2002 to 2020 on Mortality, Diabetes- Related Outcomes, Adverse Events, and Medication Expenses	82
Leisure-Time Physical Activity May Attenuate the Impact of Diabetes on Cognitive Decline in Middle-Aged and Older Adults: Findings From the ELSA-Brasil Study	81
Maternal Cardiac Changes in Women With Obesity and Gestational Diabetes Mellitus	80
Use of a Dual GIP/GLP-1 Receptor Agonist in HNF1A-MODY and HNF4A-MODY	80
Diabetic Ketoacidosis at Onset of Type 1 Diabetes and Long-term HbA1c in 7,961 Children and Young Adults in the Australasian Diabetes Data Network	80
Risk of Anaphylaxis Among New Users of GLP-1 Receptor Agonists: A Cohort Study	78
Prevalence and Predictors of Household Food Insecurity and Supplemental Nutrition Assistance Program Use in Youth and Young Adults With Diabetes: The SEARCH for Diabetes in Youth Study	77
Quantifying Environmental Waste From Diabetes Devices in the U.S.	76
Twenty-Year Temporal Trends in Risk of Ischemic Stroke in Incident Type 2 Diabetes: A Danish Population-Based Cohort Study	76
Teplizumab: A Disease-Modifying Therapy for Type 1 Diabetes That Preserves β-Cell Function	75
Accuracy and Feasibility of Real-time Continuous Glucose Monitoring in Critically Ill Patients After Abdominal Surgery and Solid Organ Transplantation	75
Predictive Value of C-Peptide Measures for Clinical Outcomes of β-Cell Replacement Therapy in Type 1 Diabetes: Report From the Collaborative Islet Transplant Registry (CITR)	74
14. Children and Adolescents: Standards of Care in Diabetes—2023	72
Genome-Wide Meta-analysis Identifies Genetic Variants Associated With Glycemic Response to Sulfonylureas	72
Effects of Integrated Care Approaches to Address Co-occurring Depression and Diabetes: A Systematic Review and Meta-analysis	72
6. Glycemic Targets: Standards of Care in Diabetes—2023	70
Preventing, Screening, and Treating Suicidality in Pediatric Type 1 Diabetes: Roles for Behavioral Health Care Professionals	69
In This Issue of Diabetes Care	69
10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2022	69
Prevalence of Charcot Foot in Subjects With Diabetes: A Nationwide Cohort Study	68
Differential Associations of GAD Antibodies (GADA) and C-Peptide With Insulin Initiation, Glycemic Responses, and Severe Hypoglycemia in Patients Diagnosed With Type 2 Diabetes	66
Association of Historical Redlining With Gestational Diabetes Mellitus: The Mediating Role of BMI and Area Deprivation Index	66
Comment on Lontchi-Yimagou et al. An Atypical Form of Diabetes Among Individuals With Low BMI. Diabetes Care 2022;45:1428–1437	65
Age of Diabetes Diagnosis and Lifetime Risk of Dementia: The Atherosclerosis Risk in Communities (ARIC) Study	65
A Special Thanks to the Reviewers of Diabetes Care	65
Short-Term Metformin Protects Against Glucocorticoid-Induced Toxicity in Healthy Subjects: A Randomized, Double-Blind, Placebo-Controlled Trial	65
Higher Neighborhood Drivability Is Associated With a Higher Diabetes Risk in Younger Adults: A Population-Based Cohort Study in Toronto, Canada	64
Issues and Events	64
Prediabetic HbA1c and Cortical Atrophy: Underlying Neurobiology	64
Depressive Symptoms Longitudinally Mediate the Effect of Hyperglycemia on Memory Decline in Type 2 Diabetes	62
Mental Health During Late Pregnancy and Postpartum in Mothers With and Without Type 1 Diabetes: The ENDIA Study	62
Associations Between Postdischarge Care and Cognitive Impairment–Related Hospital Readmissions for Ketoacidosis and Severe Hypoglycemia in Adults With Diabetes	62
30-Year Cardiovascular Disease in Type 1 Diabetes: Risk and Risk Factors Differ by Long-term Patterns of Glycemic Control	61
Carbohydrates-Last Food Order Improves Time in Range and Reduces Glycemic Variability	61
Acute-to-Chronic Glycemic Ratio as a Predictor of COVID-19 Severity and Mortality	61
Lingering Effects of Hyperglycemia in Recently Diagnosed Diabetes During Long-term Follow-up of the DCCT/EDIC and UKPDS Cohorts: More Evidence That Early Control Matters	61
Less Sitting for Preventing Type 2 Diabetes	60
Diabetes Risk Factors and Bone Microarchitecture as Assessed by High-Resolution Peripheral Quantitative Computed Tomography in Adults With Long-standing Type 1 Diabetes	60
A Biomarker-Based Score for Risk of Hospitalization for Heart Failure in Patients With Diabetes	59
Prolonged Glycemic Adaptation Following Transition From a Low- to High-Carbohydrate Diet: A Randomized Controlled Feeding Trial	58
Comparison of Serum Creatinine– and Cystatin C–Based eGFR at Baseline and Their Prediction of Incident Moderate Albuminuria in Individuals With Type 1 Diabetes	57
Trends in Preventive Care Services Among U.S. Adults With Diagnosed Diabetes, 2008–2020	57
Sodium–Glucose Cotransporter 2 Inhibitor Treatment and Risk of Atrial Fibrillation: Scandinavian Cohort Study	57
Maternal Glycemic Dysregulation During Pregnancy and Neonatal Blood DNA Methylation: Meta-analyses of Epigenome-Wide Association Studies	56
Automated Insulin Delivery: Benefits, Challenges, and Recommendations. A Consensus Report of the Joint Diabetes Technology Working Group of the European Association for the Study of Diabetes and the A	56
The Growing Role of Technology in the Care of Older Adults With Diabetes	55
Incidence and Characteristics of Remission of Type 2 Diabetes in England: A Cohort Study Using the National Diabetes Audit	54
Risk of Phimosis Associated With SGLT2i Versus GLP-1RA: A Danish Cohort Study	54
Extinguishing the Fire: Treating Pediatric Type 2 Diabetes by Targeting Obesity Treatment	54
Risks of and From SARS-CoV-2 Infection and COVID-19 in People With Diabetes: A Systematic Review of Reviews	53
Historic Residential Redlining and Diabetes: Mediating Pathways and Policy Solutions	53
Are Pediatric Primary Care Providers Ready for Type 1 Diabetes Screening and Monitoring? A Survey From a Large, U.S. Pediatric Network	53
Sodium–Glucose Cotransporter 2 Inhibitors and the Short-term Risk of Bladder Cancer: An International Multisite Cohort Study	53
Changes in β-Cell Function and Insulin Sensitivity During Treatment With Dapagliflozin Alone or in Combination With Exenatide in Type 2 Diabetes	53
Racial Disparities in Access and Use of Diabetes Technology Among Adult Patients With Type 1 Diabetes in a U.S. Academic Medical Center	52
Development and Validation of Prediction Models of Adverse Kidney Outcomes in the Population With and Without Diabetes	52
6. Glycemic Goals and Hypoglycemia: Standards of Care in Diabetes—2024	52
Introduction: Standards of Medical Care in Diabetes—2022	52
Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)	51
Fenofibrate and Heart Failure Outcomes in Patients With Type 2 Diabetes: Analysis From ACCORD	51
In This Issue of Diabetes Care	50
Impaired Awareness of Hypoglycemia and Severe Hypoglycemia in Drivers With Diabetes: Insights From the Association of British Clinical Diabetologists Nationwide Audit	50
Response to Comment on Liu et al. Incidence of Type 1 Diabetes May Be Underestimated in the Chinese Population: Evidence From 21.7 Million People Between 2007 and 2017. Diabetes Care 2021;44:2503–2509	50
To Correct or Not to Correct: Lost in Inpatient Translation	50
Diabetes Stigma and Psychosocial Outcomes in Adolescents and Young Adults: The SEARCH for Diabetes in Youth Study	49
Weighing in on Type 2 Diabetes Remission	49

All-Cause Mortality and Cardiovascular and Microvascular Diseases in Latent Autoimmune Diabetes in Adults	49
Is the Current Lifestyle Modification Approach to Diabetes Prevention in the U.S. a Success?	49
17. Diabetes Advocacy: Standards of Care in Diabetes—2024	49
Association of Water Arsenic With Incident Diabetes in U.S. Adults: The Multi-Ethnic Study of Atherosclerosis and the Strong Heart Study	48
Health Beliefs Associated With Metformin Use Among Insured Adults With Prediabetes	48
Disparities Between Teleretinal Imaging Findings and Patient-Reported Diabetic Retinopathy Status and Follow-up Eye Care Interval: A 10-Year Prospective Study	48
Is COVID-19 to Blame? Trends of Incidence and Sex Ratio in Youth-Onset Type 2 Diabetes in Germany	48
Diabetes During Pregnancy Among Immigrants in Sweden: A National Cohort Study of All Pregnant Women in Sweden	48
Trends and Demographic Disparities in Diabetes Hospital Admissions: Analyses of Serial Cross-Sectional National and State Data, 2008–2017	47
Multicenter Randomized Trial of Intermittently Scanned Continuous Glucose Monitoring Versus Self-Monitoring of Blood Glucose in Individuals With Type 2 Diabetes and Recent-Onset Acute Myocardial Infar	47
Effect of Oral Semaglutide Versus Comparators on Multiple Cardiometabolic Risk Factor Control in Adults With Type 2 Diabetes	47
Transition of BMI Status From Childhood to Adulthood and Cardiovascular-Kidney-Metabolic Syndrome in Midlife: A 36-Year Cohort Study	47
Relationships of Changes in Physical Activity and Sedentary Behavior With Changes in Physical Fitness and Cardiometabolic Risk Profile in Individuals With Type 2 Diabetes: The Italian Diabetes and Exe	47
Erratum. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2024. Diabetes Care 2024;47(Suppl. 1):S158–S178	47
Flexor Tendon Tenotomy Treatment of the Diabetic Foot: A Multicenter Randomized Controlled Trial	46
Associations of Habitual Calcium Supplementation With Risk of Cardiovascular Disease and Mortality in Individuals With and Without Diabetes	45
New-Onset Fulminant Type 1 Diabetes After SARS-CoV-2 Infection	45
The NIDDK Takes on the Complications of Type 1 Diabetes: The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study	45
Association of Insulin Resistance With Cardiovascular Disease and All-Cause Mortality in Type 1 Diabetes: Systematic Review and Meta-analysis	44
Hypoglycemic and Hyperglycemic Crises Among U.S. Adults With Diabetes and End-stage Kidney Disease: Population-Based Study, 2013–2017	44
12. Retinopathy, Neuropathy, and Foot Care:Standards of Care in Diabetes—2023	44
Safety of Empagliflozin in Patients With Type 2 Diabetes and Chronic Kidney Disease: Pooled Analysis of Placebo-Controlled Clinical Trials	44
Early Menopause and Cardiovascular Disease Risk in Women With or Without Type 2 Diabetes: A Pooled Analysis of 9,374 Postmenopausal Women	44
Painful Diabetic Neuropathy: Myofascial Pain Makes the Difference	44
High Prevalence of Prediabetes Among Asian and Pacific Islander Adolescents With Overweight or Obesity in a Primary Care Population	44
Controversies Around the Measurement of Blood Ketones to Diagnose and Manage Diabetic Ketoacidosis	44
Global Prevalence of Prediabetes	43
Association Between Age at Diabetes Diagnosis and Subsequent Incidence of Cancer: A Longitudinal Population-Based Cohort	43
Tirzepatide Associated With Reduced Albuminuria in Participants With Type 2 Diabetes: Pooled Post Hoc Analysis From the Randomized Active- and Placebo-Controlled SURPASS-1–5 Clinical Trials	43
8. Obesity and Weight Management for the Prevention and Treatment of Type 2 Diabetes: Standards of Care in Diabetes—2023	43
Summary of Revisions: Standards of Care in Diabetes—2025	43
8. Obesity and Weight Management for the Prevention and Treatment of Type 2 Diabetes: Standards of Care in Diabetes–2024	42
Severe COVID-19 Infection in Type 1 and Type 2 Diabetes During the First Three Waves in Sweden	42
About the Artist: Kathy McNamara	42
Association Between Change in Accelerometer-Measured and Self-Reported Physical Activity and Cardiovascular Disease in the Look AHEAD Trial	42
Response to Comment on Galvez-Fernandez et al. Urinary Zinc and Incident Type 2 Diabetes: Prospective Evidence From the Strong Heart Study. Diabetes Care 2022;45:2561–2569	41
Effect of Loss-of-Function Genetic Variants in PCSK9 on Glycemic Traits, Neurocognitive Impairment, and Hepatobiliary Function	41
About the Editor: Cheryl A.M. Anderson, PhD, MPH, MS: Promoting Health Equity Through Nutrition	40
Response to Comment on Kaminski et al. Assessment of Glycemic Control by Continuous Glucose Monitoring, Hemoglobin A1c, Fructosamine, and Glycated Albumin in Patients With End-Stage Kidney Disease and	40
Response to Comment on Shih et al. Increased Incidence of Pediatric Type 1 Diabetes With Novel Association With Coxsackievirus A Species in Young Children but Declined Incidence in Adolescents in Taiw	40
Issues and Events	40
Declining Incidence Rates of Distal Symmetric Polyneuropathy in People With Type 1 and Type 2 Diabetes in Denmark, With Indications of Distinct Patterns in Type 1 Diabetes	39
Symptoms of Anxiety and Depression Are Independently Associated With Impaired Awareness of Hypoglycemia in Type 1 Diabetes	39
Dipeptidyl Peptidase 4 Inhibitors and Gallbladder or Biliary Diseases: Data From the U.S. Food and Drug Administration Adverse Event Reporting System	39
Metabolic, Intestinal, and Cardiovascular Effects of Sotagliflozin Compared With Empagliflozin in Patients With Type 2 Diabetes: A Randomized, Double-Blind Study	39
Association of Continuous Glucose Monitoring Metrics With Pregnancy Outcomes in Patients With Preexisting Diabetes	39
Earlier Age at Type 2 Diabetes Diagnosis Is Associated With Increased Genetic Risk of Cardiovascular Disease	38
Ten Years of Improving Glycemic Control in Pediatric Diabetes Care: Data From the Norwegian Childhood Diabetes Registry	38
Retinal Capillary Damage Is Already Evident in Patients With Hypertension and Prediabetes and Associated With HbA1c Levels in the Nondiabetic Range	38
The National Clinical Care Commission Report to Congress: Recommendations to Better Leverage Federal Policies and Programs to Prevent and Control Diabetes	38
Comment on Abdelgani et al. Empagliflozin Reduces Liver Fat in Individuals With and Without Diabetes. Diabetes Care 2024;47:668–675	37
Body Fat Distribution, Cardiometabolic Traits, and Risk of Major Lower-Extremity Arterial Disease in Postmenopausal Women	37
Historic Residential Redlining and Present-day Diabetes Mortality and Years of Life Lost: The Persistence of Structural Racism	37
Impact of COVID-19 Vaccination on Glycemia in Individuals With Type 1 and Type 2 Diabetes: Substudy of the COVAC-DM Study	37
Impact of Type 2 Diabetes and Glycated Hemoglobin Levels Within the Recommended Target Range on Mortality in Older Adults With Cognitive Impairment Receiving Care at a Memory Clinic: NCGG-STORIES	37
The Use of Point-of-Care Bacterial Autofluorescence Imaging in the Management of Diabetic Foot Ulcers: A Pilot Randomized Controlled Trial	36
About the Artist: Appleton	36
β-Cell Function Derived From Routine Clinical Measures Reports and Predicts Treatment Response to Immunotherapy in Recent-Onset Type 1 Diabetes	36
Hunting for Progressive NAFLD in Type 2 Diabetes: Do Not Trust Liver Enzymes!	36
Response to Comment on Hamblin et al. Capillary Ketone Concentrations at the Time of Colonoscopy: A Cross-Sectional Study With Implications for SGLT2 Inhibitor–Treated Type 2 Diabetes. Diabetes Care 2	36
Comparative Cardiovascular Effectiveness and Safety of SGLT-2 Inhibitors, GLP-1 Receptor Agonists, and DPP-4 Inhibitors According to Frailty in Type 2 Diabetes	36
Risk of Infection in Older Adults With Type 2 Diabetes With Relaxed Glycemic Control	36
The Association Between Hemoglobin A1c and Complications Among Individuals With Diabetes and Severe Chronic Kidney Disease	36
Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity	35
Effect of Banded Roux-en-Y Gastric Bypass Versus Sleeve Gastrectomy on Diabetes Remission at 5 Years Among Patients With Obesity and Type 2 Diabetes: A Blinded Randomized Clinical Trial	35
Comparison of Tofogliflozin and Glimepiride Effects on Nonalcoholic Fatty Liver Disease in Participants With Type 2 Diabetes: A Randomized, 48-Week, Open-Label, Active-Controlled Trial	35
Real-world Accuracy of CGM in Inpatient Critical and Noncritical Care Settings at a Safety-Net Hospital	35
5. Facilitating Positive Health Behaviors and Well-being to Improve Health Outcomes: Standards of Care in Diabetes—2025	35
Range of Risk Factor Levels, Risk Control, and Temporal Trends for Nephropathy and End-stage Kidney Disease in Patients With Type 1 and Type 2 Diabetes	35
Continuous Glucose Monitoring Metrics and Birth Weight: Informing Management of Type 1 Diabetes Throughout Pregnancy	35
Association of Metabolic Syndrome With Incident Dementia: Role of Number and Age at Measurement of Components in a 28-Year Follow-up of the Whitehall II Cohort Study	35
Examining the Acute Glycemic Effects of Different Types of Structured Exercise Sessions in Type 1 Diabetes in a Real-World Setting: The Type 1 Diabetes and Exercise Initiative (T1DEXI)	34
Safety and Efficacy of Sustained Automated Insulin Delivery Compared With Sensor and Pump Therapy in Adults With Type 1 Diabetes at High Risk for Hypoglycemia: A Randomized Controlled Trial	34
Abatacept for Delay of Type 1 Diabetes Progression in Stage 1 Relatives at Risk: A Randomized, Double-Masked, Controlled Trial	34
10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2024	34
Introduction and Methodology: Standards of Care in Diabetes—2023	34
Erratum. Comment on Choi et al. Alcohol Abstinence and the Risk of Atrial Fibrillation in Patients With Newly Diagnosed Type 2 Diabetes Mellitus: A Nationwide Population-Based Study. Diabetes Care 202	34
Efficacy and Safety of Finerenone in Type 2 Diabetes: A Pooled Analysis of Trials of Heart Failure and Chronic Kidney Disease	34
Association of a Healthy Lifestyle With All-Cause and Cause-Specific Mortality Among Individuals With Type 2 Diabetes: A Prospective Study in UK Biobank	34
Exploring Kidney Oxygenation Responses to Dapagliflozin, Exenatide, and Their Combination in Patients With Type 2 Diabetes and Chronic Kidney Disease: Observations From a Prespecified Pilot Study of a	33
Comment on Russell et al. Abatacept for Delay of Type 1 Diabetes Progression in Stage 1 Relatives at Risk: A Randomized, Double-Masked, Controlled Trial. Diabetes Care 2023;46:1005–1013	33
Mortality in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE)	33
Protecting the Liver: Should We Substitute Fruit Juices for Sugar-Sweetened Beverages?	33
The Glucose Management Indicator: Time to Change Course? Diabetes Care 2024;47:906–914	33
NIDDK at 75 Years of Age: Great Triumphs but Concerns for Its Longevity	33
HLA Class II (DR, DQ, DP) Genes Were Separately Associated With the Progression From Seroconversion to Onset of Type 1 Diabetes Among Participants in Two Diabetes Prevention Trials (DPT-	33
Response to Comment on Dawed et al. Genome-Wide Meta-analysis Identifies Genetic Variants Associated With Glycemic Response to Sulfonylureas. Diabetes Care 2021;44:2673–2682	33
Comment on Yang et al. GLP-1RAs for Ischemic Stroke Prevention in Patients With Type 2 Diabetes Without Established Atherosclerotic Cardiovascular Disease. Diabetes Care 2022;45:1184–1192	33
Association of Diabetic Ketoacidosis at Onset, Diabetes Technology Uptake, and Clinical Outcomes After 1 and 2 Years of Follow-up: A Collaborative Analysis of Pediatric Registries Involving 9,269 Chil	33
Proteomic Predictors of Incident Diabetes: Results From the Atherosclerosis Risk in Communities (ARIC) Study	32
Evaluation of the Clinical Impact of Dapagliflozin Discontinuation as Adjunctive Therapy for Patients With Type 1 Diabetes After Indication Withdrawal: A Two-Center Retrospective Study	32
Continuous Glucose Monitoring Metrics Predict All-Cause Mortality in Diabetes: A Real-world Long-term Study	32
Erratum. A Multicenter Prospective Evaluation of the Benefits of Two Advanced Hybrid Closed-Loop Systems in Glucose Control and Patient-Reported Outcomes in a Real-world Setting. Diabetes Care 2024;47	32
Association of COVID-19 and Development of Type 1 Diabetes: A Danish Nationwide Register Study	32
Comment on Wong et al. Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference for Patients With Obesity or Overweight: A Systematic Review, Meta-analysis, and Meta-regression	32